As device developers of all sizes grapple with the updated transition timeline for EU MDR compliance and the recent EU AI Act approval falls short of expectations, the question looms: how can regul
Despite exciting advancements and new investments into the field, the development of new RNAi therapeutics is plagued by difficulties with extra-hepatic delivery and scale-up of manufacturi
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
